Oncaspar

Therapeutic Indication:

Oncaspar is indicated as a component of antineoplastic combination therapy in Acute Lymphoblastic Leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.

• Composition: Pegaspargase 3750 Units/5 ml.
• Pharmaceutical Form: Powder for Solution for Injection or Infusion.
• Method of Administration: Intravenous or intramuscular.
• How Supplied: Single 5 ml vial.
• Manufacturer: Les Laboratoires Servier, France.